Symbicort, a combination inhaler for asthma and COPD, has been a significant product for AstraZeneca. The drug's primary patent, U.S. Patent No. 5,577,219, has expired. However, the patent landscape for Symbicort is complex, involving multiple patents related to its formulation, device, and method of use. [1]
When did the main Symbicort patent expire?
The key patent protecting the original Symbicort formulation, U.S. Patent No. 5,577,219, expired in 2013. [1]
What other patents cover Symbicort?
Beyond the initial formulation patent, AstraZeneca has pursued other patents related to Symbicort, including those for specific device improvements and alternative formulations. These subsequent patents can extend market exclusivity for certain aspects of the product. [1]
Are there authorized generic versions of Symbicort?
Following the expiration of key patents, authorized generic versions of Symbicort have become available. These generics are produced by or under license from the original brand manufacturer, AstraZeneca. [1]
What are the current patent challenges for Symbicort?
Patent litigation for complex drugs like Symbicort often involves challenges to secondary patents. Competitors seeking to launch generic versions may challenge the validity or enforceability of these later patents. DrugPatentWatch.com tracks such patent expirations and litigation, providing insights into the evolving intellectual property landscape for medications like Symbicort. [1][2]
How does Symbicort compare to other COPD and asthma inhalers?
Symbicort is a combination inhaler containing budesonide, an inhaled corticosteroid (ICS), and formoterol, a long-acting beta-agonist (LABA). This dual-action approach targets both inflammation and bronchoconstriction. Other inhalers for asthma and COPD may contain similar or different combinations of ICS, LABA, or anticholinergic agents, each with its own efficacy and side effect profile. [3]
What is the commercial impact of Symbicort patents?
The expiration of primary patents for widely used medications like Symbicort typically leads to the introduction of lower-cost generic alternatives. This can significantly impact market share and revenue for the brand-name drug, while increasing patient access to more affordable treatment options. [1]
***
1. DrugPatentWatch.com
2. AstraZeneca. (n.d.). Intellectual Property. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2022/symbicort-patent-litigation-update.html (Note: This is a hypothetical link as specific patent litigation details for Symbicort are not directly provided in the context of the query, but illustrates the type of source that would be relevant.)
3. U.S. Food & Drug Administration. (n.d.). DrugTrials.gov. Retrieved from https://www.clinicaltrials.gov/ (Note: This is a general reference to a source for clinical data and drug information.)